2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents

The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade...

Full description

Saved in:
Bibliographic Details
Published inAnnals of pediatric endocrinology & metabolism Vol. 28; no. 3; pp. 168 - 177
Main Authors Kim, Su Jin, Kim, Ji Hyun, Hong, Yong Hee, Chung, In Hyuk, Lee, Eun Byoul, Kang, Eungu, Kim, Jinsup, Yang, Aram, Rhie, Young-Jun, Yoo, Eun-Gyong, Shin, Young-Lim, Choi, Jin Ho, Kim, Soo Young, Lee, Jieun
Format Journal Article
LanguageEnglish
Published Korean Society of Pediatric Endocrinology 01.09.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The Committee of Central Precocious Puberty of Korean Pediatrics and Adolescents of the Korean Society of Pediatric Endocrinology has newly developed evidence-based 2022 clinical practice guidelines for central precocious puberty in Korean children and adolescents. These guidelines provide the grade of recommendations, which includes both the strength of recommendations and the level of evidence. In the absence of sufficient evidence, recommendations are based on expert opinion. These guidelines have been revised and supplement the previous guidelines "Clinical Guidelines for Precocious Puberty 2011," and are drawn from a comprehensive review of the latest domestic and international research and the grade of recommendation appropriate to the domestic situation. This review summarizes the newly revised guidelines into 8 key questions and 27 recommendations and consists of 4 sections: screening, diagnosis, treatment, and long-term outcome of central precocious puberty.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current affiliation: Department of Clinical Development at Novel Pharma, Inc.
ISSN:2287-1012
2287-1292
DOI:10.6065/apem.2346168.084